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Abstract
Background: MicroRNAs (miRNAs) have been implicated in the incidence and progression of cancer. It has been
proposed that single nucleotide polymorphisms (SNPs) influence cancer risk due to their position within genes
involved in miRNA synthesis and regulation.
Methods: Genes directly and indirectly involved in miRNA biogenesis were identified from the literature. We then
identified SNPs within these regions. Using genome-wide association study data we evaluated associations
between biogenesis-related SNPs with colon cancer risk and their corresponding mRNA expression in normal
colonic mucosa and carcinoma and difference in expression between the two tissues. SNPs that were associated
with either altered colon cancer risk or with mRNA expression were evaluated for associations with altered miRNA
expression.
Results: Eleven SNPs were associated (P < 0.05) with colon cancer risk, and two of these variants remained significant
after correction for multiple comparisons (PHolm < 0.05): rs1967327 (PRKRA) (ORdom = 0.78, 95 % CI 0.66–0.92) and
rs4548444 (MAPKAP2) (ORrec = 1.67, 95 % CI 1.12–2.48). Of these two SNPs, rs4548444 (MAPKAP2), was associated with
significantly altered miRNA expression levels in normal colonic mucosa, with nine miRNAs upregulated among
individuals homozygous rare (GG) for rs4548444. One SNP associated with cancer prior to adjustment for multiple
comparisons, rs11089328 (DGCR8), was associated with altered levels of hsa-miR-645 in differential tissue under the
dominant model. Three SNPs, rs2740349 (GEMIN4) in carcinoma tissue, and rs235768 (BMP2) and rs2059691 (PRKRA) in
normal mucosa, were significantly associated with altered mRNA expression levels across genotypes after multiple
comparison adjustment. Rs2740349 (GEMIN4) and rs235768 (BMP2) were significantly associated with the upregulation
of six and nine individual miRNAs in normal colonic mucosa, respectively.
Conclusion: Our data suggest that few of the SNPs in biogenesis genes we evaluated alter levels of mRNA
transcription or colon cancer risk. As only one SNP both alters colon cancer risk and miRNA expression it is likely that
SNPs influencing cancer do not do so through miRNAs. Because the significant SNPs were associated with
downregulated mRNAs and upregulated miRNAs, and because each SNP was associated with unique miRNAs, it is
possible that other mechanisms influence mature miRNA levels.
Keywords: miRNA, Biogenesis, SNP, Colon, Cancer, Risk
* Correspondence: Lila.Mullany@hsc.utah.edu
1Department of Internal Medicine, University of Utah, School of Medicine,
Salt Lake City, UT, USA
Full list of author information is available at the end of the article
© 2016 Mullany et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mullany et al. BMC Medical Genomics  (2016) 9:21 
DOI 10.1186/s12920-016-0181-x
Background
Mature microRNAs (miRNAs) are non-coding RNA
molecules, ~22 nucleotides (nt) in length [1–5], which
act as endogenous, post-transcriptional regulators of
messenger RNAs (mRNAs). By binding to complemen-
tary mRNA molecules, they are able to impede mRNA
translation or cause mRNA degradation [6], depending
on the degree of complementarity shared between the
miRNA and mRNA [7]. As such, miRNAs alter the
translated protein product levels of these genes within
the specific biological tissues and diseases [8] in which
they are expressed. It has been suggested that single
nucleotide polymorphisms (SNPs) within miRNA gene
regions that are associated with cancer risk may function
by altering miRNA expression [9]. Similarly, SNPs within
any of the genes regulating miRNA biogenesis would
have the potential to alter the expression of mature miR-
NAs and subsequently cancer risk [10].
There are many transcriptional and post-transcriptional
[11] modification steps necessary for producing mature
miRNAs. Genes directly involved in splicing, exporting
and RNA editing events [12], as well as accessory proteins
[13], have the potential to impact miRNA expression
levels. MiRNA biogenesis can be broken down into four
main categories of events: transcription, nuclear process-
ing, cytoplasmic processing and RNA-induced silencing
complex (RISC) formation and loading [11, 12]. We pro-
vide a brief overview of miRNA biogenesis.
Transcription
Primary-miRNAs (pri-miRNAs) are transcribed by RNA
polymerase II [11, 14], and produce transcripts of up to
1 kilobase (kb) in length [11]. They consist of potentially
more than one co-transcribed precursor miRNA se-
quence (pre-miRNA), as illustrated by miRNAs orga-
nized in a polycistronic cluster [15]. Transcription
factors, such as TP53 and MYC, and epigenetic regula-
tion, such as histone modifications, can alter miRNA
transcription [11]. Once transcribed, pri-miRNAs fold
into hairpin structures, consisting of a stem sequence
(~35 nt), a terminal loop and single-RNA strands at both
the 5′ and 3′ ends [11, 12]. These hairpin structures are
recognized as substrates for the ribonuclease (RNase) III
enzymes Drosha and Dicer [13].
Nuclear processing
Pre-miRNAs are generated by the cleavage of the pri-
miRNA in the nucleus of the cell by the Microprocessor,
which is comprised of Drosha and DiGeorge Syndrome
Critical Region 8 (DGCR8) [12, 16]. The stem and tail
regions of the pri-miRNA are important for the first
cleavage: DGCR8 binds to the pri-miRNA using these
regions and serves to align Drosha with the pri-miRNA
to cleave at the appropriate site, which is approximately
11 base pairs (bps), or 1 helical turn [17], away from the
junction of the single and double strands within the
hairpin [12]. GSK3β has been shown to phosphorylate
Drosha in the cytoplasm before it enters the nucleus,
which enables it to be localized to the nucleus and
contribute to miRNA biogenesis [18]. Drosha-mediated
cleavage results in a hairpin of ~65–70 bps [11, 13] and
leaves behind a ~2 nt overhang on the 3′ end, which is
characteristic of RNase III enzymes [19], and makes it
possible for the pri-miRNA to be recognized by and sub-
sequently transported out of the nucleus and into the
cytoplasm by the Exportin-5 (XPO5) [17, 19] -Ran-GTP
complex [7, 12]. Adenosine-Deaminase, RNA-Specific
(ADAR) genes act on pre-mRNA transcripts, editing ad-
enosine to inosine, which acts similarly to guanosine
during translation, potentially altering protein function
[20]. Because ADARs work on nuclear, double-stranded
RNA structures, it is likely that they edit pri-miRNA
transcripts prior to their export from the nucleus. Also
acting in the nucleus, transforming growth factor-β
(TGF-β) and bone morphogenetic protein factors
(BMPs) have been shown to increase Microprocessor ac-
tivity through the recruitment of SMAD proteins and
DDX5 to the miRNA transcript, enhancing processing
by Drosha [12] and potentially increasing miRNA
expression.
Cytoplasmic processing
Once in the cytoplasm, the pre-miRNA is cleaved by
Dicer, which forms a complex with TRBP (or TARBP2,
trans-activating response RNA binding protein) complex
to produce the two strands of miRNA duplex [12]. Dicer
removes the loop of the pre-miRNA hairpin, cleaving
about 2 helical turns from the base of the hairpin [17],
leaving behind ~22 bps of the miRNA/*miRNA duplex
(where * is pronounced “star” [17]) [12]. Serine phos-
phorylation of TRBP by mitogen-activated protein kinase
(MAPK)/extracellular regulated kinase (ERK) has been
shown to stabilize TRBP [13]. Dicer activity has been
shown to be impaired by decreased levels of TRBP [13];
as such SNPs within TRBP or MAPK/ERK could poten-
tially lead to altered processing of pre-miRNAs.
MiRISC formation and loading
Of the two strands of the mature miRNA duplex gener-
ated by Dicer cleavage, the guide strand is typically the
strand with the more unstable 5′ end [12, 21]. This
strand is selected by the Argonaute (AGO1-4) protein
and loaded into the RISC with the help of the RISC-
loading complex, which has been proposed to be com-
prised of Dicer and TRBP [11, 13]. The other strand, the
star strand, is usually degraded [17]. Loading of the
guide strand into the complex stabilizes the miRNA
[22], protecting it from degrading nucleases within the
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cytoplasm, and enables it to bind to its target mRNA to
induce silencing of the transcript. Helicases, such as the
DEAD-Box proteins (GEMIN3 and p68), GEMIN4 and
MOV10, are important for miRNA duplex unwinding
and miRISC formation and activity [12].
There are additional accessory genes associated with
miRNA biogenesis. Trinucleotide repeat-containing pro-
teins (TRNC6A or GW182, TRNC6B, TRNC6C) and fra-
gile X mental retardation protein (FMRP, encoded by
FMR1) are correlated with the presence of cytoplasmic
p-bodies, which are involved in mRNA degradation by
miRNAs, and can impact the effect of miRNAs on their
targets [13]. MiRNA stability, and therefore expression,
has been linked to mRNA target presence and ability to
be bound to the miRISC [22, 23]; as such, SNPs within
genes that regulate mRNA degradation may impact
mature miRNA expression levels. LIN28B regulates
Microprocessor activity and LIN28 regulates dicing of
pre-let-7 through the regulatory sequence “GGAG” in
the pre-miRNA’s terminal loop [12, 13, 24, 25]; LIN28
binds to this region and recruits terminal uridine
transferase (TUT4 or ZCCHC11), which subsequently
uridylates the pre-miRNA and inhibits processing by
Dicer [13, 24, 25].
In this study, we investigate the risk of developing
colon cancer associated with SNPs found within
miRNA-biogenesis genes. We also analyze each SNP
with mRNA expression of its corresponding gene in nor-
mal colonic mucosa, carcinoma tissue and difference in
expression between normal colonic mucosa and carcin-
oma to determine if these SNPs alter mRNA transcrip-
tion. Based on these results, we analyze those SNPs
associated with either altered colorectal cancer (CRC)
risk or with altered mRNA expression of its correspond-
ing gene with miRNA expression in normal colonic mu-
cosa and differential miRNA expression between
carcinoma tissue and normal colonic mucosa across ge-
notypes. As genes involved in the biogenesis of miRNAs
are involved in production of virtually all miRNAs, we
hypothesize that SNPs in these genes will alter mRNA
expression by causing aberrant transcription as well as




The study population consisted of individuals previously
enrolled in a study of Diet, Lifestyle and Colon cancer at
the University of Utah and the Kaiser Permanente Med-
ical Research Program (KPMRP) [26] for whom Genome
Wide Association Study (GWAS) and miRNA expres-
sion data were available. Study subjects included inci-
dent cases of colon cancer between the ages of 30 and
79 who were non-Hispanic white, Hispanic or African
American and were able to provide a signed informed
consent prior to participation in the study. All stages of
tumor were included in the study population and in this
analysis. The study was approved by the University of
Utah Institutional Review Board for Human Subjects.
miRNA processing
RNA (miRNA) was extracted from formalin-fixed paraf-
fin embedded tissues and processed as previously de-
scribed [27]. 100 nanograms (ng) total RNA was labeled
with Cy3 and hybridized to Agilent Human miRNA
Microarray V19.0 and were scanned on an Agilent Sur-
eScan microarray scanner model G2600D using Agilent
Feature Extract software v.11.5.1.1. Data were required
to pass stringent quality control (QC) parameters estab-
lished by Agilent that included tests for excessive back-
ground fluorescence, excessive variation among probe
sequence replicates on the array, and measures of the
total gene signal on the array to assess low signal. If
samples failed to meet QC standards, the sample was re-
peated. If a sample failed QC assessment a second time
the sample was deemed to be of poor quality and was
excluded from down-stream analysis. The Agilent plat-
form was found to be highly reliable (r = 0.98) and had
reasonable agreement with NanoString [28] and excel-
lent agreement with quantitative reverse transcription
polymerase chain reaction (qRT-PCR) [29]. If data were
missing from normal colonic mucosa but the tumor tis-
sue was successfully scanned (N = 60), we imputed
values for normal mucosa as previously described in
[30]; this method of imputation has yielded results with
high accuracy. To minimize differences that could be at-
tributed to the array, amount of RNA, location on array
or other factors that could erroneously influence expres-
sion, total gene signal was normalized by multiplying
each sample by a scaling factor which was the median of
the 75th percentiles of all the samples divided by the
75th percentile of each individual sample [31]. This scal-
ing factor was implemented using SAS 9.4.
RNA-Seq sequencing library preparation
Total RNA was available from 197 carcinoma and nor-
mal mucosa pairs. These samples were taken from the
study subjects used for miRNA analysis and were
extracted, isolated and purified in the same manner as
previously described [27]. RNA library construction was
done with the Illumina TruSeq Stranded Total RNA
Sample Preparation Kit with Ribo-Zero. The samples
were then fragmented and primed for complementary
DNA (cDNA) synthesis, adapters were then ligated onto
the cDNA, and the resulting samples were then ampli-
fied using PCR; the amplified library was then purified
using Agencount AMPure XP beads. A more detailed
description of the methods can be found in our previous
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work [32]. Of these, 175 passed QC based on acceptable
number of sequence reads for both carcinoma tissue and
normal mucosa. Of these, 71 subjects also had GWAS
data available for comparison with mRNA and miRNA
expression data in carcinoma tissue, 67 for normal co-
lonic mucosa, and 61 for the difference between normal
colonic mucosa and carcinoma tissue.
RNA sequencing and data processing
Sequencing was done using an Illumina TruSeq v3 single
read flow cell and a 50 cycle single-read sequence run
was performed on an Illumina HiSeq instrument. Reads
were then aligned to a sequence database containing the
human genome (build GRCh37/hg19, February 2009
from genome.ucsc.edu) and alignment was performed
using novoalign v2.08.01. Python and a pysam library
were used to calculate counts for each exon and UTR of
the genes using a list of gene coordinates obtained from
http://genome.ucsc.edu. We dropped features that were
not expressed in our data or for which the expression
was missing for the majority of samples. A more detailed
description of the methods can be found in our previous
work [32].
Targeted SNPs from GWAS for biogenesis genes
SNP identification and bioinformatics analysis
A literature search was conducted to identify genes in-
volved in miRNA biogenesis, as well as SNPs within bio-
genesis genes that alter cancer risk, by searching
PubMed and standard search engines for peer-reviewed
articles containing keywords “miRNA” and “biogenesis”,
and the subsequent addition of other words that
appeared in preliminary searches or those that would
yield more specific results such as “degradation”, “pro-
cessing”, “polymorphism”, “SNP” and “cancer” [10–13,
16, 17, 20, 22, 23, 33, 34]. This included the all genes
directly associated with miRNA biogenesis (such as
DROSHA, DICER, DGCR8, TARBP2, AGO1-4, GEMIN3/
4) as well as accessory genes, or genes indirectly associ-
ated with biogenesis (such as ADARs, BMPs, SMADs,
FMR1, DDXs, DHXs, LIN28, MOV10, ZCCHC11,
MAPKs, GSK3β, p38, p54). NCBI SNP (http://
www.ncbi.nlm.nih.gov/snp/) [35] was used to identify
SNPs within these genes. We filtered results for ‘only
Human active’, ‘snp’, with a custom minor allele fre-
quency (MAF) range of 0.01–1.0; some gene-SNP associ-
ations were identified from the literature and as such
were not screened for these criteria. This list repre-
sents the majority of SNPs within major human
miRNA biogenesis genes. To better evaluate the
impact of these SNPs on the expression of the pro-
teins, we utilized Ensembl’s Variant Effect Predictor
(VEP) tool (http://grch37.ensembl.org/info/docs/tools/
vep/index.html) [36]; we used the archived, GRCh37,
which corresponds to our GWAS and mRNA data.
GWAS genotyping
GWAS data were obtained using Illumina HumanHap
550, 610 K as part of the GECCO study and has been
described previously [37]. Imputation to HapMap2 Re-
lease 24 was performed using MACH, which was im-
puted to HapMap Release 22 using BEAGLE. All SNP
coordinates were defined using hg19/GRCh37. We ex-
cluded SNPs from consideration that failed Illumina
quality measures or standard quality control procedures
[38]. We further excluded SNPs that showed limited
variability in our data. In total, we evaluated 219 SNPs
with colon cancer risk; those that were significant were
then evaluated with all miRNAs expressed in normal co-
lonic mucosa in at least 5 % of the population. The final
list of included SNPs can be seen in Table 1.
Statistical analysis
Our sample consisted of 401 cases who had both
miRNA and SNP data and 1115 cases and 1173 controls
with SNP data for colon cancer risk assessment. We
used a logistic regression model adjusted for age, sex
and study center to identify SNPs associated with colon
cancer risk; we report odds ratios (OR) and 95 % confi-
dence intervals (CI) from those models. We adjusted for
multiple comparisons using the step-down Bonferroni
correction [39] based upon the effective number of inde-
pendent SNPs per chromosome as determined using the
SNP spectral decomposition method proposed by Nyholt
[40] and modified by Li and Ji [41]. SNPs that were sig-
nificantly associated with colon cancer risk were then
assigned either a dominant or recessive model. SNPs
were also compared with mRNA RNA-Seq expression
data. Out of the 219 candidate SNPs, 215 had sufficient
variant allele expression to evaluate with mRNA expres-
sion. We required at least one subject with RNA-Seq ex-
pression in both tumor and normal tissue and to have
the heterozygous genotype to evaluate a dominant
model or the homozygous variant genotype to evaluate
both the dominant and recessive models. The means of
the mRNA expression data for each tissue type as mea-
sured by the log base 2 of the RPKM (Reads per Kilo-
base per Million) were compared in both the dominant
and recessive (where possible) genotypes of each SNP.
The p-values are based upon 10,000 permutations of the
genotype using the coin package in R, and the results
were adjusted for multiple comparisons at the chromo-
somal level using the false discovery rate (FDR) [42] level
of 0.05. After adjustment for multiple comparisons, any
significant SNPs were then combined with the SNPs
found to be significantly associated with colorectal can-
cer risk and evaluated for associations with miRNA
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Table 1 Included SNPs and action and location of involved miRNA biogenesis genes
Geneb SNP IDa Active
Loc.d
Process
ADAR rs11264222, rs1127309, rs1127313, rs1127314, rs1127317, rs2131902,
rs2229857, rs2335230, rs3766925, rs376692, rs4845384
N Pre-miRNA Editing
AGO1 rs636832, rs11584005f, rs595055c C miRISC Formation/Loading
AGO2 rs10087629, rs1060832, rs11166984, rs11166985, rs13276958,
rs1878478, rs2176397, rs2271735, rs2292775, rs2292780, rs2293939,
rs2944761, rs2944767, rs2944776, rs2977469, rs2977477, rs2977490,
rs3735805, rs3864659, rs3928672, rs4961278, rs6985156, rs7009635,
rs7824304, rs7843258, rs7460a, rs2944760
AGO3 rs10796876, rs274732, rs4351606
AGO4 rs12044203, rs12119583
BMP2 rs15705, rs2273073, rs235768, rs3178250 N Recruitment of SMAD/Enhancement of Drosha
BMP3 rs3733549
BMP4 rs17563, rs76335800f
BMP6 rs1043784, rs1044104, rs7764128, rs9505298
DCP1B rs2240610, rs6489338 C Localization with AGO & P-bodies/mRNA Decapping for
Degradation
DDX10 rs10890898, rs2726920 C Pre-miRNA Unwinding/Possible Drosha Processing
Enhancement. DDX5-DDX17 Required for Recognition of
pri-miRNA By Drosha.DDX11 rs1808348, rs2075321, rs7953706, rs9750
DDX13
(SKIV2L)
rs437179 (rs438999, rs449643 only SKIV2L)




DGCR8 rs11089328, rs1558496, rs1640297, rs17817767, rs2073778,
rs2286926, rs2286928, rs41281429, rs417309, rs9606248
N Pri-miRNA Cleavage
DHX15 rs6841898 C May Interact with AGO1/2, Dicer, TRBP/Facilitate mi/siRNA
Loading (DHX6,9).
DHX16 rs3130000
DICER1 rs10149095, rs1057035, rs11160231, rs11622643, rs11624081,
rs1209904, rs12323635, rs12897280, rs13078, rs17091855, rs3742330,
rs4513027, rs1110386, rs11621737
C Pre-miRNA Cleavage
DROSHA rs10052174, rs10067066, rs10068052, rs10719, rs11748548,
rs13169883, rs13183642, rs16901109, rs16901165, rs17408227,
rs17408716, rs17409624, rs17409803, rs17410035, rs17485323,
rs2279797, rs2287584, rs3792830, rs3805525, rs4867329f, rs4867339,
rs493760, rs524138, rs573010, rs639174, rs6450848, rs673019,
rs6878195, rs6884823, rs7447423, rs7712155, rs7712436, rs7719666,
rs13175906a, rs2330696a, rs6883386a, rs7702984f
N Pri-miRNA Cleavage
FMR1 rs25704f C P-bodies and mRNA Degradation
GEMIN4 rs1045481, rs1062923, rs2251689, rs2291778, rs2740348, rs2740349,
rs3744741, rs7813, rs28685132f, rs2740351
C miRNA Duplex Unwinding (miRISC formation)
GSK3β rs3732361, rs56728675, rs60393216 C Drosha Phosphorylation/Stabilization
LIN28 rs11247946, rs11587947a N Recruites ZCCHC11 to miRNA for Uridylation
LIN28A rs12741800a, rs12728900, rs6598964, rs6697410
LIN28B rs12194974, rs17065417 Microprocessor Regulation
MAP3K19 rs13390171f, rs1551497f, rs2322254f C TRBP Phosphorylation/Stabilization




MAPKAPK2 rs4240847, rs4548444, rs45514798
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expression levels in normal colonic mucosa as well as
with differential miRNA expression between carcinoma
tissue and normal colonic mucosa. We compared log
base 2 transformed expression levels across selected
genotype models using the significance analysis of mi-
croarrays (SAM) technique in the R package siggenes
[43], p-values were based upon 1000 permutations with
an FDR level of 0.10. For siggenes, SNPs were evaluated
as either dominant or recessive based on previous find-
ings, since a two-level outcome is more interpretable.
Bioinformatics analysis utilized UCSC Table Browser
[44] to obtain all SNP coordinates; all coordinates are
from the GRCh37 assembly.
Results
Eleven SNPs were associated (P < 0.05) with colon
cancer risk (Table 2). After adjustment for multiple com-
parisons, two of these SNPs remained significant (PHolm
< 0.05): rs10207436 (PRKRA) (ORAG/GG = 0.78, 95 % CI
0.66–0.92) and rs4548444 (MAPKAP2) (ORGG = 1.67,
95 % CI 1.12–2.48). For rs3178250 (BMP2) (ORTC/CC =
1.18, 95 % CI 0.99–1.40) we observed that the heterozy-
gote genotype (relative to homozygous normal) was as-
sociated with ~25 % elevated colon cancer risk, while
the rare homozygous variant genotype was (non-signifi-
cantly) associated with reduced risk. The dominant
model did not reach statistical significance. PRKRA
rs10207436 was associated with reduced colon cancer
risk (under the dominant model), while MAPKAPK2
rs4548444 was associated with increased risk (under the
recessive model).
Three SNPs in total were associated with altered
mRNA expression across genotypes. Two SNPs,
rs2059691 (PRKRA) under the dominant model and
rs235768 (BMP2) under the recessive model, were asso-
ciated with altered mRNA expression in normal colonic
mucosa after multiple corrections (FDR = 0.003, 0.035
respectively) (Table 3). One SNP, rs2740349 (GEMIN4)
Table 1 Included SNPs and action and location of involved miRNA biogenesis genes (Continued)
MOV10 rs2932538 C miRNA Duplex Unwinding (miRISC formation)






rs3800373, rs755658 C Localization with P-bodies/mRNA Degradation and/or
Storage








RAN rs10848237, rs14035, rs3809142, rs10773831 Both Ran-GTP Associates with XPO5 for Export
SMAD4 rs948588 N Drosha Processing Enhancement
TGFB1 rs1800468, rs1800470f, rs1800471, rs1800472 N Recruitment of SMAD/Enhancement of Drosha
TNRC6A
(GW182)
rs1030211, rs11639856, rs11642302, rs11644976, rs12917810,
rs1633445, rs2303085, rs4788430, rs6497755,











XPO5 rs1106841, rs11077, rs17287964, rs2257082, rs699937, rs7755135 Both Nuclear Export of Pre-miRNA to Cytoplasm
ZCCHC11
(TUT4)
rs2274147, rs835036 C Uridylation of Pre-miRNA/Dicer Inhibition
a Related SNPs are those in high linkage disequilibrium (rb > 0.8). These are: rs7460 (rs11996715); rs197381 (rs197383); rs13175906 (rs13186629); rs2330696
(rs6450839); rs6883386 (rs2161006, rs17404622); rs11587947 (rs11581746); rs12741800 (rs3811463); rs7291691 (rs9623117)
b Some of these genes reflect actual location (SNP is within gene), others reflect literature associations
c AGO genes are also known by EIF2C (i.e.AGO1 is also known by EIF2C1, etc.…)
d N: Nucleus; C: Cytoplasm
edbSNP lists this SNP’s position as LOC101927027; it is associated in the literature with PRKRA in the literature (falling within an accepted range of PRKRA)
f These SNPs were either not evaluated for association with CRC due to unavailability of GWAS data
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Table 2 Associations between biogenesis genes and cancer risk for those SNPs that had a raw p-value of <0.05
Controls Cases
N % N % OR (95 % CI) P-valuea,b P Holmb VEP Prediction
AGO2 (rs6985156)
GG 912 77.7 858 77.0 1.00 0.030 0.395
GA 250 21.3 230 20.6 0.98 (0.80, 1.20)
AA 11 0.9 27 2.4 2.59 (1.27, 5.26)
GG/GA vs. AA 11 0.9 27 2.4 2.6 (1.28, 5.28) Modifier
AGO2 (rs7843258)
CC 810 69.1 779 69.9 1.00 0.031 0.395
CT 342 29.2 298 26.7 0.90 (0.75, 1.08)
TT 21 1.8 38 3.4 1.87 (1.09, 3.23)
CC/CT vs.TT 21 1.8 38 3.4 1.93 (1.12, 3.32) Modifier
AGO2 (rs2176397)
CC 567 48.3 568 50.9 1.00 0.019 0.273
CT 517 44.1 435 39.0 0.85 (0.71, 1.01)
TT 89 7.6 112 10.0 1.26 (0.93, 1.71)
CC/CT vs. TT 89 7.6 112 10 1.36 (1.02, 1.83) Modifier
AGO2 (rs4961278)
AA 605 51.6 578 51.8 1.00 0.032 0.395
AG 501 42.7 444 39.8 0.92 (0.78, 1.09)
GG 67 5.7 93 8.3 1.45 (1.04, 2.03)
AA/AG vs. GG 67 5.7 93 8.3 1.51 (1.09, 2.09) Modifier
BMP2 (rs3178250)
TT 747 63.7 663 59.5 1.00 0.014 0.040
TC 371 31.6 415 37.2 1.24 (1.04, 1.48)
CC 55 4.7 37 3.3 0.75 (0.49, 1.16)
TT vs.TC/CC 426 36.3 452 40.5 1.18 (0.99, 1.40) Modifier
DGCR8 (rs11089328)
AA 400 34.1 432 38.7 1.00 0.009 0.066
AG 586 50.0 491 44.0 0.76 (0.63, 0.91)
GG 187 15.9 192 17.2 0.94 (0.74, 1.20)
AA vs. AG/GG 773 65.9 683 61.3 0.80 (0.68, 0.96) Modifier
DROSHA (rs2287584)
TT 743 63.3 742 66.5 1.00 0.032 0.384
TC 394 33.6 325 29.1 0.82 (0.69, 0.99)
CC 36 3.1 48 4.3 1.33 (0.85, 2.08)
TT/TC vs. CC 36 3.1 48 4.3 1.42 (0.91, 2.20) Low
DROSHA (rs17410035)
GG 552 47.1 468 42.0 1.00 0.014 0.181
GT 473 40.3 518 46.5 1.29 (1.08, 1.53)
TT 148 12.6 129 11.6 1.01 (0.77, 1.32)
GG vs. GT/TT 621 52.9 647 58.0 1.22 (1.03, 1.44) Modifierc
GEMIN4 (rs2740348)
CC 782 66.7 798 71.6 1.00 0.048 0.241
CG 352 30.0 286 25.7 0.80 (0.67, 0.96)
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was significantly associated with altered mRNA expres-
sion in carcinoma tissue, under the dominant model
(FDR = 0.047).
Results from VEP showed that five SNPs within four
genes had a predicted ‘moderate’ effect, meaning that
the SNP is a “non-disruptive variant that might change
protein effectiveness” [36]. These SNPs were: rs235768
(BMP2), rs2740348 and rs2740349 (GEMIN4) (which are
in high Linkage Disequilibrium (LD) but both included
for their separate results in Tables 3 and 4), rs449643
(SKIV2L) and rs1140409 (DDX5). Two SNPs, rs1106841
and rs2257082 (XPO5), had a predicted ‘low’ effect,
meaning that they are assumed “to be mostly harmless
or unlikely to change protein behavior” [36]. All other
SNPs were categorized as having a ‘modifier’ impact,
meaning that there is little evidence of impact due to the
SNPs being in non-coding regions [36].
Twenty-four unique miRNAs were dysregulated in
total with SNPs that were either significantly associated
with altered mRNA expression or cancer risk. Twenty-
three of these were seen in normal colonic mucosa
across genotypes; eight of these were associated with
rs4548444 (MAPKAPK2) under the recessive genotype,
six with rs2740349 (GEMIN4) under the dominant geno-
type, and nine with rs235768 (BMP2) under the reces-
sive genotype (Table 4). One miRNA, hsa-miR-645, was
seen to be significantly associated with rs11089328
(DGCR8) in differential tissue expression under the
dominant genotype.
Discussion
As the vast majority of mature miRNAs are generated
by a group of genes either directly or indirectly related
to miRNA biogenesis, SNPs within these genes could
alter miRNA expression and subsequently colon cancer
risk. Of the 219 SNPs within the miRNA biogenesis-
related genes we analyzed, 11 SNPs were significantly as-
sociated with colon cancer. Three of these were signifi-
cantly associated with colon cancer after correction for
multiple comparisons. Of these, only DGCR8
rs11089328 and MAPKAPK2 rs4548444, were associated
with altered miRNA expression when an FDR level of
0.1 was applied.
We previously reported, in a study with a larger sam-
ple size, that rs3178250 (BMP2) was associated with in-
creased risk (ORTC/CC 1.20 95 % CI 1.05, 1.38) of
developing colon cancer, as well as rectal cancer (ORCC
1.63 95 % CI 1.02, 2.60) [45]. The larger sample of ap-
proximately 500 cases provided adequate power to de-
tect a significant association for this SNP. BMP2 is a
member of the TGF-β superfamily which has been asso-
ciated with colorectal cancer [46]. Currently to our
knowledge there are no significant associations between
the other significant SNPs we identified and colorectal
cancer in the literature.
Of the 212 SNPs evaluated with mRNA expression, 48
SNPs within 18 genes were associated with altered
mRNA expression in either normal colonic mucosa, car-
cinoma tissue or difference in expression between nor-
mal colonic mucosa and carcinoma tissue; three of these
remained significant after adjustment for multiple com-
parisons. One of these three SNPs, rs2740349
(GEMIN4), was associated with altered mRNA expres-
sion in carcinoma tissue, and the two other SNPs,
rs2059691 (PRKRA) and rs235768 (BMP2), were associ-
ated with altered levels of mRNA expression in normal
colonic mucosa across genotypes. Both rs2740349
(GEMIN4), under the dominant model and rs235768
(BMP2), under the recessive model, had less mRNA ex-
pression with the variant allele. Rs2059691 (PRKRA) had
Table 2 Associations between biogenesis genes and cancer risk for those SNPs that had a raw p-value of <0.05 (Continued)
GG 39 3.3 31 2.8 0.78 (0.48, 1.27)
CC vs. CG/GG 391 33.3 317 28.4 0.80 (0.67, 0.96) Moderate
MAPKAPK2 (rs4548444)
AA 713 60.8 686 61.5 1.00 0.021 0.041
AG 417 35.5 363 32.6 0.91 (0.76, 1.08)
GG 43 3.7 66 5.9 1.61 (1.08, 2.40)
AA/AG vs. GG 43 3.7 66 5.9 1.67 (1.12, 2.48) Modifier
PRKRA (rs10207436)
AA 616 52.5 655 58.7 1.00 0.013 0.026
AG 480 40.9 400 35.9 0.78 (0.66, 0.93)
GG 77 6.6 60 5.4 0.75 (0.52, 1.07)
AA vs. AG/GG 557 47.5 460 41.3 0.78 (0.66, 0.92) Modifier
a Adjusted for age, sex and center
b These p-values are for the co-dominant model only
c This SNP is predicted to have a ‘modifier’ effect for C5orf22 by VEP
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Gene SNP Model N Meanc mRNA expression Raw FDR N Mean mRNA expression Raw FDR Raw FDR
ADAR rs3766925 TT 38 831.03 0.047 0.749 36 426.06 Modifier
TA/AA 33 518.97 31 306.42
AGO2 rs7460b AA 19 284.79 0.027 0.316 18 113.50 0.021 0.267 Modifier
AT/TT 52 160.38 49 70.65
AGO2 rs1060832 CC/CT 70 191.79 66 83.06 0.050 0.403 Modifier
TT 1 326.00 1 23.00
AGO2 rs13276958 TT/TC 56 172.75 51 88.39 0.022 0.403 Modifier
CC 15 271.80 16 62.31
AGO2 rs2176397 CC/CT 66 174.39 0.043 0.316 60 78.37 Modifier
TT 5 448.20 7 114.71
AGO2 rs2271735 CC/CA 66 205.17 0.009 0.223 61 88.84 0.019 0.267 Modifier
AA 5 42.00 6 14.33
AGO2 rs2292775 GG/GA 70 191.79 66 83.06 0.049 0.403 Modifier
AA 1 326.00 1 23.00
AGO2 rs2292780 CC/CT 70 191.79 66 83.06 0.048 0.403 Modifier
TT 1 326.00 1 23.00
AGO2 rs2293939 GG/GA 65 204.00 0.039 0.316 60 85.65 Low
AA 6 81.83 7 52.29
AGO2 rs2944760 TT/TG 67 190.13 63 84.56 0.038 0.403 Modifier
GG 4 253.00 4 44.50
AGO2 rs2944761 GG 18 272.83 0.039 0.316 17 104.76 0.049 0.365 Modifier
GA/AA 53 166.79 50 74.48
AGO2 rs2977490 GG 21 161.81 0.034a 0.316 17 131.29 0.016 0.267 Modifier
GA/AA 50 207.06 50 65.46
AGO2 rs10087629 GG 22 300.91 0.005 0.223 21 115.14 0.009 0.267 Modifier
GA/AA 49 145.53 46 67.11
BMP2 rs15705 AA/AC 68 26.35 0.039 0.308 64 63.50 Modifier
CC 3 43.33 3 70.33
BMP2 rs235768 TT/TA 63 28.84 58 71.78 0.003 0.035 0.049 0.535 Moderate
AA 8 13.13 9 12.44
DCP1B rs2240610 GG/GA 52 29.46 51 12.47 0.009 0.127 Modifier
AA 19 31.79 16 29.00
DCP1B rs6489338 GG/GA 54 28.48 53 12.30 0.004 0.114 Modifier
AA 17 35.18 14 32.00
DDX5 rs1140409 AA 68 710.12 0.044 0.292 64 562.19 Moderate
AC/CC 3 212.67 3 88.33
DHX16 rs3130000 GG 60 80.68 55 63.58 0.045 0.696 Modifier
GA/AA 11 64.36 12 74.08
DICER1 rs4513027 AA/AG 65 348.18 61 286.57 0.047 0.554 Modifier
GG 6 290.00 6 64.50
DROSHA rs573010 CC 38 230.03 37 87.57 0.038 0.769 Modifier
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Table 3 SNPs associated with mRNA expression in normal mucosa, carcinoma tissue and differential across genotypes (Continued)
CA/AA 33 172.42 30 108.30
DROSHA rs673019 AA 61 221.62 0.015 0.361 60 102.13 Modifier
AG/GG 10 91.20 7 51.57
DROSHA rs2330696 GG 46 224.61 40 88.18 0.008 0.470 Modifier
GA/AA 25 163.96 27 109.70
DROSHA rs3792830 AA/AG 70 200.31 0.028 0.361 66 95.74 Modifier
GG 1 409.00 1 170.00
DROSHA rs3805525 TT/TC 61 207.46 57 87.16 0.050 0.569 0.026 0.769 Modifier
CC 10 177.60 10 152.10
DROSHA rs6878195 TT 23 174.43 20 56.10 0.020 0.569 Modifier
TC/CC 48 217.06 47 114.19
DROSHA rs7719666 CC/CT 49 214.47 48 112.17 0.034 0.569 Modifier
TT 22 178.27 19 58.16
DROSHA rs10052174 AA/AG 70 200.31 0.030 0.361 66 95.74 Modifier
GG 1 409.00 1 170.00
DROSHA rs10067066 TT/TC 70 200.31 0.028 0.361 66 95.74 Modifier
CC 1 409.00 1 170.00
DROSHA rs13183642 GG 44 169.70 39 79.23 0.030 0.569 Modifier
GT/TT 27 257.93 28 121.39
DROSHA rs16901165 GG/GA 70 200.31 0.029 0.361 66 95.74 Modifier
AA 1 409.00 1 170.00
FAM57A rs2740351 AA/AG 58 42.79 54 20.30 0.006 0.089 Modifier
GG 13 24.92 13 4.54
FKBP5 rs755658 CC 59 122.02 56 179.54 0.042 0.232 Modifier
CT/TT 12 82.50 11 69.09
GEMIN4 rs7813 AA/AG 58 59.29 54 32.72 0.023 0.113 Modifier
GG 13 28.62 13 8.69
GEMIN4 rs2740348 CC 51 64.31 47 35.26 0.013 0.089 Moderate
CG/GG 20 26.55 20 11.15
GEMIN4 rs2740349 TT 51 64.31 0.005 0.047 47 35.26 0.012 0.089 Moderate
TC/CC 20 26.55 20 11.15
MAPK1 rs743409 GG/GA 60 280.25 56 201.55 0.032 0.979 Modifier
AA 11 341.64 11 126.00
MAPK14 rs8510 CC 60 246.67 56 147.52 0.016 0.157 Modifier
CT/TT 11 193.64 11 62.91
PRKRA rs2059691b GG 33 48.67 0.044a 0.428 30 15.37 0.000 0.003 Modifier
GA/AA 38 89.16 37 51.24
RBBP6 rs2033214 TT 58 200.36 56 130.27 0.038 0.418 Modifier
TG/GG 13 119.23 11 51.00
SKIV2L rs449643 CC 52 73.13 0.016 0.458 50 51.50 Moderate
CT/TT 19 136.58 17 95.35
TARBP2 rs34649330 CC/CT 69 22.33 0.037 0.685 65 10.69 0.024 0.640 Modifier
TT 2 51.50 2 10.00
TNRC6A rs1030211 AA 56 266.98 0.044 0.299 55 228.71 Modifier
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more expression in the GA/AA genotype as compared
to the GG rarer genotype. While rs2740349 (GEMIN4)
and rs235768 (BMP2) were both predicted by VEP to
have a ‘moderate’ effect on the host gene, rs2059691
(PRKRA) was predicted to have a ‘modifier’ effect. Sub-
sequently, rs2740349 (GEMIN4) and rs235768 (BMP2)
were both shown to be associated with altered levels of
miRNA expression and in both cases all miRNAs were
upregulated in the corresponding variant genotypes.
Conversely, rs2059691 (PRKRA) was not predicted to
have any effect, and we saw increased levels of mRNA
expression in the variant genotype, and no subsequent
miRNA expression associations.
MAPKAPK2 rs4548444 was associated with an in-
crease in mean miRNA expression in normal colonic
mucosa tissue, however this increase was seen with
only the homozygote rare genotype. This SNP is asso-
ciated with increased risk of colon cancer (ORGG 1.61
95 % CI 1.08, 2.40). MAPK/ERK proteins have been
shown to phosphorylate TRBP, stabilizing it and
potentially increasing Dicer-mediated processing of
pre-miRNAs. A SNP in MAPKAPK2 could cause an
altered binding affinity of MAPKAPK2 to TRBP,
thereby impacting mature miRNA production. As we
did not see any association between rs4548444 and
MAPKAPK2 mRNA expression, and we saw an in-
crease in miRNA expression in the GG (homozygous
rare) genotype, this indicates that while the SNP is
associated with colon cancer risk and miRNA expres-
sion, it is not doing so through altered miRNA bio-
genesis. MAPKAPK2 is involved in many cellular
processes, including stress and inflammatory response,
gene regulation and cell proliferation, and nuclear ex-
port [47]; as such, it is possible that the increased
risk of colon cancer is associated with another bio-
logical process that MAPKAPK2 regulates.
Using Ensembl’s VEP to predict the effect of each SNP
on its corresponding gene showed that very few SNPs
were predicted to have any effect. There were five SNPs
within four genes that had a ‘moderate’ effect. Of these,
only one was seen to be associated with altered colon
cancer risk, rs2740348 (GEMIN4), which is in LD with
rs2740349 (GEMIN4). While there were no significant
associations were seen between rs2740348 and miRNA
expression or mRNA expression, we did see significant
findings after correction for multiple comparisons for
mRNA and for miRNA expression with rs2740349
(GEMIN4). However, miRNA expression was upregu-
lated in the same genotype with which mRNA expres-
sion was downregulated; this suggests that this SNP
increases miRNA expression. Because the helicase
GEMIN4 is thought to aid in miRNA duplex unwinding
[12], a reduction in GEMIN4 transcription should theor-
etically result in reduced miRNA biogenesis. Similarly,
BMPs have been thought to enhance Drosha cleavage
[12], thereby increasing mature miRNA levels. As we see
that the opposite is the case, and that miRNA levels in-
crease with the reduction of BMP2 and GEMIN4 tran-
scription, it is possible that other mechanisms influence
miRNA biogenesis, or these genes have additional roles
in biogenesis.
Interestingly, all of the miRNAs that were dysregulated
were unique, in that no one miRNA was associated with
more than one SNP. None of these miRNAs is listed as
a known target in miRTarBase, a repository of validated
miRNA target associations (http://mirtarbase.mbc.nc-
tu.edu.tw/) [48] at this time, and there are no common-
alities of chromosomal location between the SNPs and
their respectively associated miRNAs. This suggests that
miRNA biogenesis may be specific to the level of the in-
dividual miRNA, and the reason these specific groups of
miRNAs are dysregulated across genotypes is because
Table 3 SNPs associated with mRNA expression in normal mucosa, carcinoma tissue and differential across genotypes (Continued)
AG/GG 15 189.33 12 138.83
TNRC6A rs4788430 GG 41 298.59 0.010 0.212 39 252.33 Modifier
GA/AA 30 184.97 28 157.29
TNRC6A rs6497755 AA 23 316.39 0.030 0.299 22 303.50 0.009 0.194 Modifier
AC/CC 48 219.04 45 168.18
XPO5 rs11077 TT/TG 57 178.12 55 70.96 0.017 0.157 Modifier
GG 14 328.86 12 134.83
XPO5 rs1106841 AA/AC 59 183.85 57 73.46 0.036 0.232 Low
CC 12 325.83 10 133.40
XPO5 rs2257082 GG/GA 66 208.95 62 75.56 0.012 0.157 Low
AA 5 193.20 5 167.20
a This p-value is for the recessive model
b This mRNA was significantly differentially expressed across genotypes using both the recessive and dominant models
c Means are displayed in count data (rather than RPKMs)
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these genes affect these specific miRNA’s production.
Winter et al. describe findings to support that “specific
helicases may regulate miRNAs differentially” [12]; this
would support subsets of miRNAs associated with differ-
ent SNPs. Perhaps other proteins have a similar influ-
ence on specific miRNA biogenesis.
Biogenesis genes contribute to the processing of virtu-
ally every mature miRNA, however miRNA expression is
thought to be tissue specific. One limitation of our study
is that our findings could be influenced by our use of tis-
sue from colon cancer patients, evaluating both normal
colonic mucosa as well as differentially expressed
miRNAs between carcinoma and normal colonic mu-
cosa. Since we only evaluated associations with miRNA
expression levels for SNPs associated with colon cancer
risk or mRNA expression, other SNPs in biogenesis
genes could alter miRNAs in other situations. It should
also be kept in mind that many of the accessory genes to
miRNA biogenesis are involved in multiple biological
pathways. Thus, it is possible that SNPs could alter
colon cancer risk through multiple mechanisms. Add-
itionally, because we only looked at more commonly oc-
curring SNPs (MAF ≥0.01) and we required there to be
at least one subject in our dataset with the homogeneous
Table 4 SNPs, previously identified as significantly associated with either mRNA expression or cancer after multiple comparisons,
associated with miRNA expression at an FDR level of 0.10
SNP miRNA N Mean miRNA expression N Mean miRNA expression P-valuesd
Normal Colonic Mucosa
AA/AG GG
rs4548444 (MAPKAPK2)b hsa-miR-3163 376 9.46 25 11.35 0.0033
hsa-miR-378c 376 7.03 25 8.72 0.0084
hsa-miR-4316 376 6.74 25 8.22 0.0003
hsa-miR-4444 376 8.51 25 9.85 0.0035
hsa-miR-4753-5p 376 7.84 25 9.50 0.0059
hsa-miR-509-5p 376 7.73 25 9.35 0.0040
hsa-miR-5195-5p 376 8.24 25 10.16 0.0076
hsa-miR-659-3p 376 10.83 25 12.85 0.0095
hsa-miR-770-5p 376 5.93 25 7.11 0.0030
TT TC/CC
rs2740349 (GEMIN4)a hsa-miR-145-5p 280 184.32 121 229.78 0.0011
hsa-miR-378a-3p 280 145.01 121 163.22 0.0005
hsa-miR-378i 280 72.24 121 80.89 0.0013
hsa-miR-4428 280 1322.42 121 1442.51 0.0017
hsa-miR-451a 280 23.52 121 41.62 0.0021
hsa-miR-494 280 15338.94 121 16994.17 0.0013
TT/TA AA
rs235768 (BMP2)a hsa-miR-1321 357 4.89 44 6.17 0.0034
hsa-miR-206 357 10.43 44 12.25 0.0032
hsa-miR-23a-5p 357 5.98 44 6.61 0.0045
hsa-miR-30c-2-3p 357 4.70 44 5.51 0.0001
hsa-miR-3189-3p 357 6.49 44 7.27 0.0032
hsa-miR-4494 357 9.63 44 10.62 0.0021
hsa-miR-4648 357 9.00 44 9.99 0.0017
hsa-miR-4707-3p 357 8.05 44 9.75 0.0001
Differential (between carcinoma tissue and normal colonic mucosa)
AA AG/GG
rs11089328 (DGCR8)c hsa-miR-645 140 1.27 243 2.14 0.0002
a SNP significantly associated with mRNA expression after correction for multiple comparisons
b SNP significantly associated with cancer after correction for multiple comparisons
c SNP associated with cancer, but not significantly after correction for multiple comparisons
d Raw p-value
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variant genotype in order to analyze the dominant and
recessive genotypes and at least one subject with the
heterozygous genotype to evaluate the dominant model
and overall CRC risk, another possible limitation is that
more rare, and possibly more deleterious, SNP associa-
tions were not evaluated in this study.
We hypothesized that SNPs within biogenesis genes
could impact the transcription of these mRNAs, and
therefore impact miRNA expression. Out of the 212
SNPs evaluated with mRNA expression only three were
significantly associated with altered expression after cor-
rection for multiple comparisons. This indicates that, in
colon cancer, the majority of these SNPs do not nega-
tively impact biogenesis gene transcription. While other
mechanisms could still alter cellular protein levels, and
thus possibly miRNA biogenesis, within the cell, we are
not able to measure this. We also hypothesized that
SNPs in biogenesis genes would be associated colon can-
cer risk and that miRNA expression levels would be in-
fluenced by the genotype of these SNPs. However, out of
219 SNPs within 48 genes, only one SNP was associated
with both altered colon cancer risk and altered miRNA
expression levels. Because the SNP that was associated
with both colon cancer risk and miRNA expression
belongs to the MAPK family, and as such is involved in
many processes other than miRNA biogenesis, the
impact on cancer and even on miRNA expression may
be due to other mechanisms unrelated to miRNA bio-
genesis. This finding suggests that SNPs in miRNA bio-
genesis genes have minimal impact on colon cancer risk
and those that were associated have minimal associa-
tions with miRNAs.
Conclusion
Our data suggest that few of the SNPs in biogenesis
genes we evaluated alter levels of mRNA transcription
or colon cancer risk. As only one SNP both alters colon
cancer risk and miRNA expression it is likely that SNPs
influencing cancer do not do so through miRNAs.
Because the significant SNPs were associated with down-
regulated mRNAs and upregulated miRNAs, and be-
cause each SNP was associated with unique miRNAs, it
is possible that other mechanisms influence mature
miRNA levels.
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